• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ERT launched refreshed eCOA technology environment

ERT launched refreshed eCOA technology environment

February 10, 2017
CenterWatch Staff

ERT, a global data and technology company that minimizes risk and uncertainty in clinical trials, has announced the launch of its refreshed eCOA technology environment, which dramatically simplifies the implementation and management of trials that require collection of Clinical Outcomes Assessments.

Designed to support simple to the most complex studies, ERT’s eCOA environment collects patient data anywhere, anytime, and in any language, and can be provisioned across mobile devices, web browers and patients’ own devices (known as BYOD or bring your own device). On-device calculations and medical device integrations enable real-time access to operational and clinical data, so sponsors see how their study is performing, and ensure patient safety.

“We are shattering the commonly-held misconception that a paper-based solution is easier or less expensive than technology,” said Ron Sullivan, executive vice president, eCOA at ERT. “ERT’s eCOA environment has all the quality, consistency and administrative benefits inherent with an electronic solution, and now is easy to implement and even easier to manage.”

ERT’s eCOA environment provides uniform data collection with more efficient study change management and mitigates the need for manual data reconciliation. Formerly customized features are now included as standard, and pre-configured study components are widely available. Additionally, complimentary protocol review by ERT’s expansive team of patient reported outcomes (PRO)/eCOA Clinical Scientists ensures fit-for-purpose design on every study.

“Now we can enable sponsors to focus on clinical research—not the minutiae of data collection and assimilation,” continued Sullivan. “Trial leaders can reduce uncertainty and have confidence in their collected data, while keeping studies on time and on budget.”

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing